<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 的股价在周四交易前出现下跌。该股票此前收于 58.00 美元，但开盘价为 53.37 美元。Hims
&amp; Hers Health 的股票最后交易价格为 54.38 美元，成交量为 15,902,838 股。</p>
<p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Hims
&amp; Hers 股票在 UnitedHealth 抛售后会好吗？</li>
</ul>
<p>HIMS 已经成为多份研究分析报告的主题。瑞银集团在 5 月 6 日的研究报告中重申了对 Hims
&amp; Hers Health 股票的 “混合” 评级。Canaccord Genuity Group 将 Hims
&amp; Hers Health 的目标价格从 38.00 美元上调至 68.00 美元，并在 2 月 19 日的研究报告中给予该公司 “买入” 评级。Needham
&amp; Company LLC 在 5 月 6 日的研究报告中重新发布了 “买入” 评级，并设定了 61.00 美元的目标价格。花旗集团在 5 月 6 日的报告中重申了 “卖出” 评级，并将 Hims
&amp; Hers Health 的目标价格设定为 30.00 美元（之前为 25.00 美元）。最后，Piper Sandler 在 5 月 6 日的研究报告中重申了 “中性” 评级，并将目标价格上调至 39.00 美元（之前为 35.00 美元）。两位投资分析师对该股票给予了卖出评级，八位分析师给予了持有评级，四位分析师给予了买入评级。根据 MarketBeat 的数据，Hims
&amp; Hers Health 的共识评级为 “持有”，共识目标价格为 37.67 美元。</p>
<p>** 阅读我们对 Hims
&amp; Hers Health 的最新分析 **</p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 3.0%</p>
<ul>
<li>Hims
&amp; Hers 股票图表显示强劲的牛市延续</li>
</ul>
<p>该股票的市值为 125.9 亿美元，市盈率为 127.74，贝塔值为 1.84。该公司的 50 日简单移动平均线为 37.10 美元，200 日简单移动平均线为 34.54 美元。</p>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近在 5 月 5 日发布了季度财报。该公司报告本季度每股收益为 0.20 美元，超出市场共识预期的 0.12 美元，超出幅度为 0.08 美元。该公司本季度的收入为 5.8601 亿美元，而分析师预期为 5.3521 亿美元。Hims
&amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。该公司的收入同比增长了 110.7%。去年同期，该公司每股收益为 0.05 美元。平均而言，卖方分析师预测 Hims
&amp; Hers Health, Inc.在当前年度的每股收益将为 0.29 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>Hims
&amp; Hers 股票因基本面和挤压潜力而上涨</li>
</ul>
<p>在相关消息中，内部人士 Patrick Harrison Carroll 在 3 月 18 日的交易中出售了 23,287 股该公司的股票。该股票以平均价格 34.31 美元出售，总价值为 798,976.97 美元。交易后，内部人士现在拥有 209,661 股公司股票，价值为 7,193,468.91 美元。这笔交易代表其持股减少了 10.00%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席财务官 Oluyemi Okupe 在 5 月 15 日的交易中出售了 11,581 股公司的股票。该股票以平均价格 60.22 美元出售，总交易额为 697,407.82 美元。出售后，首席财务官现在直接拥有 113,816 股公司的股票，价值约为 6,853,999.52 美元。这笔交易代表其持股减少了 9.24%。该出售的披露信息可以在这里找到。在上个季度，内部人士共出售了 618,936 股公司股票，价值为 25,182,692 美元。当前公司股票的 13.71% 由公司内部人士持有。</p>
<h2>对 Hims</h2>
<p>&amp; Hers Health 的对冲基金看法</p>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Farallon Capital Management LLC 在第四季度将其在 Hims
&amp; Hers Health 的持仓增加了 64,338.5%。Farallon Capital Management LLC 现在拥有 8,377,000 股公司股票，价值为 202,556,000 美元，此前在该期间内又购买了 8,364,000 股。Arrowstreet Capital Limited Partnership 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 192.0%。Arrowstreet Capital Limited Partnership 现在拥有 6,304,202 股公司股票，价值为 152,436,000 美元，此前在上个季度又购买了 4,145,305 股。先锋集团在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 11.1%。先锋集团现在拥有 20,257,116 股公司股票，价值为 489,817,000 美元，此前在该期间内又购买了 2,020,722 股。Nuveen LLC 在第一季度购买了 Hims
&amp; Hers Health 的新头寸，价值约为 58,403,000 美元。最后，永荣香港资产管理有限公司在第四季度购买了 Hims
&amp; Hers Health 的新股份，价值为 41,104,000 美元。机构投资者和对冲基金目前持有公司股票的 63.52%。</p>
<h2>关于 Hims</h2>
<p>&amp; Hers Health</p>
<p>(获取免费报告)</p>
<p>Hims
&amp; Hers Health, Inc.运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Hims
&amp; Hers Health 更好</li>
<li>内部人士出售的解释：它能否影响你的投资选择？</li>
<li>3 只长期投资者在任何市场中都能喜爱的买入持有股票</li>
<li>3 只值得购买的医疗保健分红股票</li>
<li>这四位顶级投资者在第一季度购买了超过 600 万股 Broadcom 股票</li>
<li>如何投资生物技术股票</li>
<li>买入低点？3 只有望大幅反弹的石油股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Hims & Hers Health（纽约证券交易所代码：HIMS）股价从 58.00 美元跳空下跌至 53.37 美元，随后交易，最终收于 54.38 美元，成交量为 15,902,838 股。分析师的评级不一，目标价格范围在 30.00 美元至 68.00 美元之间。公司报告每股收益为 0.20 美元，超出预期，营收为 5.8601 亿美元，同比增长 110.7%。内部人士最近出售了大量股份，而机构投资者则增加了持股。该股票的市值为 125.9 亿美元，市场共识评级为 “持有”，目标价格为 37.67 美元</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $58.00, but opened at $53.37. Hims &amp; Hers Health shares last traded at $54.38, with a volume of 15,902,838 shares.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 的股价在周四交易前出现下跌。该股票此前收于 58.00 美元，但开盘价为 53.37 美元。Hims
&amp; Hers Health 的股票最后交易价格为 54.38 美元，成交量为 15,902,838 股。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Will Hims &amp; Hers Stock Be Okay After UnitedHealth's Sell-Off?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 股票在 UnitedHealth 抛售后会好吗？</li>
</ul>
</div><p>HIMS has been the subject of several research analyst reports. UBS Group reiterated a &#34;mixed&#34; rating on shares of Hims &amp; Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group increased their target price on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, February 19th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $61.00 target price on shares of Hims &amp; Hers Health in a research report on Tuesday, May 6th. Citigroup reaffirmed a &#34;sell&#34; rating and issued a $30.00 price target (up previously from $25.00) on shares of Hims &amp; Hers Health in a report on Tuesday, May 6th. Finally, Piper Sandler reiterated a &#34;neutral&#34; rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims &amp; Hers Health in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Hims &amp; Hers Health has a consensus rating of &#34;Hold&#34; and a consensus target price of $37.67.</p>
<div class="lb-trans"><p>HIMS 已经成为多份研究分析报告的主题。瑞银集团在 5 月 6 日的研究报告中重申了对 Hims
&amp; Hers Health 股票的 “混合” 评级。Canaccord Genuity Group 将 Hims
&amp; Hers Health 的目标价格从 38.00 美元上调至 68.00 美元，并在 2 月 19 日的研究报告中给予该公司 “买入” 评级。Needham
&amp; Company LLC 在 5 月 6 日的研究报告中重新发布了 “买入” 评级，并设定了 61.00 美元的目标价格。花旗集团在 5 月 6 日的报告中重申了 “卖出” 评级，并将 Hims
&amp; Hers Health 的目标价格设定为 30.00 美元（之前为 25.00 美元）。最后，Piper Sandler 在 5 月 6 日的研究报告中重申了 “中性” 评级，并将目标价格上调至 39.00 美元（之前为 35.00 美元）。两位投资分析师对该股票给予了卖出评级，八位分析师给予了持有评级，四位分析师给予了买入评级。根据 MarketBeat 的数据，Hims
&amp; Hers Health 的共识评级为 “持有”，共识目标价格为 37.67 美元。</p>
</div><p><strong>Read Our Latest Analysis on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p>** 阅读我们对 Hims
&amp; Hers Health 的最新分析 **</p>
</div><h2>Hims &amp; Hers Health Stock Down 3.0%</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 3.0%</p>
</div><ul>
<li>Hims &amp; Hers Stock Chart Points to Strong Bullish Continuation</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 股票图表显示强劲的牛市延续</li>
</ul>
</div><p>The stock has a market capitalization of $12.59 billion, a P/E ratio of 127.74 and a beta of 1.84. The business has a 50-day simple moving average of $37.10 and a two-hundred day simple moving average of $34.54.</p>
<div class="lb-trans"><p>该股票的市值为 125.9 亿美元，市盈率为 127.74，贝塔值为 1.84。该公司的 50 日简单移动平均线为 37.10 美元，200 日简单移动平均线为 34.54 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the business posted $0.05 earnings per share. On average, sell-side analysts forecast that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近在 5 月 5 日发布了季度财报。该公司报告本季度每股收益为 0.20 美元，超出市场共识预期的 0.12 美元，超出幅度为 0.08 美元。该公司本季度的收入为 5.8601 亿美元，而分析师预期为 5.3521 亿美元。Hims
&amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。该公司的收入同比增长了 110.7%。去年同期，该公司每股收益为 0.05 美元。平均而言，卖方分析师预测 Hims
&amp; Hers Health, Inc.在当前年度的每股收益将为 0.29 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 股票因基本面和挤压潜力而上涨</li>
</ul>
</div><p>In related news, insider Patrick Harrison Carroll sold 23,287 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the transaction, the insider now owns 209,661 shares in the company, valued at $7,193,468.91. This trade represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the sale, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 618,936 shares of company stock valued at $25,182,692. 13.71% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Patrick Harrison Carroll 在 3 月 18 日的交易中出售了 23,287 股该公司的股票。该股票以平均价格 34.31 美元出售，总价值为 798,976.97 美元。交易后，内部人士现在拥有 209,661 股公司股票，价值为 7,193,468.91 美元。这笔交易代表其持股减少了 10.00%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席财务官 Oluyemi Okupe 在 5 月 15 日的交易中出售了 11,581 股公司的股票。该股票以平均价格 60.22 美元出售，总交易额为 697,407.82 美元。出售后，首席财务官现在直接拥有 113,816 股公司的股票，价值约为 6,853,999.52 美元。这笔交易代表其持股减少了 9.24%。该出售的披露信息可以在这里找到。在上个季度，内部人士共出售了 618,936 股公司股票，价值为 25,182,692 美元。当前公司股票的 13.71% 由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>对 Hims</h2>
<p>&amp; Hers Health 的对冲基金看法</p>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Farallon Capital Management LLC raised its position in shares of Hims &amp; Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Hims &amp; Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. raised its holdings in Hims &amp; Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the period. Nuveen LLC bought a new position in Hims &amp; Hers Health in the first quarter valued at approximately $58,403,000. Finally, Yong Rong HK Asset Management Ltd bought a new stake in Hims &amp; Hers Health in the 4th quarter valued at $41,104,000. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Farallon Capital Management LLC 在第四季度将其在 Hims
&amp; Hers Health 的持仓增加了 64,338.5%。Farallon Capital Management LLC 现在拥有 8,377,000 股公司股票，价值为 202,556,000 美元，此前在该期间内又购买了 8,364,000 股。Arrowstreet Capital Limited Partnership 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 192.0%。Arrowstreet Capital Limited Partnership 现在拥有 6,304,202 股公司股票，价值为 152,436,000 美元，此前在上个季度又购买了 4,145,305 股。先锋集团在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 11.1%。先锋集团现在拥有 20,257,116 股公司股票，价值为 489,817,000 美元，此前在该期间内又购买了 2,020,722 股。Nuveen LLC 在第一季度购买了 Hims
&amp; Hers Health 的新头寸，价值约为 58,403,000 美元。最后，永荣香港资产管理有限公司在第四季度购买了 Hims
&amp; Hers Health 的新股份，价值为 41,104,000 美元。机构投资者和对冲基金目前持有公司股票的 63.52%。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims</h2>
<p>&amp; Hers Health</p>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc.运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1</li>
<li>How to Invest in Biotech Stocks</li>
<li>Buy the Dip? 3 Oil Stocks Poised for a Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Hims
&amp; Hers Health 更好</li>
<li>内部人士出售的解释：它能否影响你的投资选择？</li>
<li>3 只长期投资者在任何市场中都能喜爱的买入持有股票</li>
<li>3 只值得购买的医疗保健分红股票</li>
<li>这四位顶级投资者在第一季度购买了超过 600 万股 Broadcom 股票</li>
<li>如何投资生物技术股票</li>
<li>买入低点？3 只有望大幅反弹的石油股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health（纽约证券交易所代码：HIMS）股价跳空下跌 - 以下是原因